William Blair analyst Ryan Daniels has maintained their bullish stance on TMDX stock, giving a Buy rating yesterday.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Ryan Daniels has given his Buy rating due to a combination of factors that indicate a strong financial outlook for TransMedics Group. The company is expected to surpass consensus sales and earnings per share (EPS) forecasts for the current quarter, driven by robust flight volumes and organ transplant data.
Specifically, the analysis suggests that second-quarter revenue could reach approximately $163 million, which is significantly higher than the current market estimate of $146.7 million. This optimistic projection is further bolstered by consistent monthly organ transplant activities, especially in liver transplants, which constitute a major portion of the company’s revenue.
In another report released yesterday, TD Cowen also maintained a Buy rating on the stock with a $170.00 price target.
Based on the recent corporate insider activity of 55 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of TMDX in relation to earlier this year.